Phase 2 N=50 Low Dose Arsenic Trioxide as a Potential Chemotherapy Protector
Cancer Other Than Leukemia
Primary: Dose of Arsenic That Blocks Activation of p53 — 0.005 mg/kg
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=39 Effect of Increased Light Exposure on Fatigue in Breast Cancer
Breast Cancer
Primary: Fatigue — 15.25; 21.6 units on a scale
Phase 2 N=45 A Study of Chemo +/- Low-dose Radiation as Induction Therapy in SCCHN
Head and Neck Cancer · Larynx
Primary: Primary Site Complete Response Rate — 6; 4 Participants
Phase 1 N=27 Acute Exercise Cardioprotection From Doxorubicin
Breast Cancer
Primary: Global Longitudinal Strain — 19.2; -19.6; 21.4; -21.5 % deformation
Phase 3 N=260 Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer
Primary: Survival Without Grade 3 or 4 Toxicity — 3.2; 0.7 months — p=<0.001
Phase 4 N=33 Chemotherapy for Patients With Non-Small Cell Lung Cancer
Non-small Cell Lung Cancer
Primary: Proportion of Participants With a Complete or Partial Response (Objective Response Rate [ORR]) — 0.182 proportion of responders
Phase 2 N=39 Chemotherapy, Surgery, and Radiation Therapy in Treating Patients With Gastric Cancer
Gastric Cancer
Primary: Grade 3 or Higher Toxicity Incidence on Step 1 — 65.8 percentage of participants
N/A N=20 Acupuncture on Chemotherapy-induced Peripheral Neuropathy
Randomized Controlled Trial · Breast Cancer · Chemotherapy-induced Peripheral Neuropathy
Primary: The Average Pain Severity in the Brief Pain Inventory-Short Form(BPI-SF) — 3.10; 3.10; 1.72; 3.50 score on a scale
N/A N=40 Effect of Chemotherapy With Paclitaxel/Cisplatin on Development Dysgeusia in Non Small Cell Lung Cancer
Non-Small Cell Lung Cancer · Dysgeusia · Taste Disorders
Primary: Dysgeusia (UMAMI Perception) — .3; .3 μmol/ml — p=0.013
Phase 3 N=74 Effect of Zoledronic Acid on Chemotherapy Induced Bone Loss
Non-Hodgkin's Lymphoma · Lymphoma
Primary: Percentage Change in Bone Mineral Density (BMD) T-Score From Baseline to 12 Months — 0.08; -0.09 Percentage Change of BMD
Phase 2 N=62 Chemotherapy, Radiation Therapy and Immunotherapy Prior to Surgery in Operable Esophageal Cancer
Esophageal Cancer
Primary: Pathologic Complete Response (pCR) Rate — 18 Participants
Phase 2 N=30 Primary Chemotherapy With Docetaxel-Capecitabine and Doxorubicin-Cyclophosphamide in Breast Cancer
Breast Cancer · Breast Neoplasm
Primary: Number of Participants With Adverse Events — 9; 20 Participants
N/A N=20 Aprepitant's Effect on Drug Metabolism in Multi-Day Combination (CHOP/R-CHOP) Chemotherapy Regimen in Lymphoma Patients
Lymphoma
Primary: Geometric Mean Area Under Curve (AUC) of Analyte, Cyclophosphamide (CP), in Aprepitant Treatment and Control Group — 300; 250 ug/mL*hr
Phase 3 N=546 Chemotherapy and Radiation Therapy After Surgery in Treating Patients With Stomach or Esophageal Cancer
Esophageal Cancer · Gastric Cancer
Primary: Overall Survival — 3.6; 3.5 years
Phase 2 N=103 A Study of Chemotherapy Treatment for Patients With Ovarian Cancer
Ovarian Cancer · Fallopian Tube Cancer · Primary Peritoneal Cancer
Primary: Percentage of Participants With Complete Response and Partial Response (Objective Response Rate) — 7.5; 0; 3.1 percentage of participants
N/A N=52 Clinical Trial of a Novel Dose Adjustment Algorithm for Preventing Cytopenia-Related Delays During FOLFOX Chemotherapy
Colorectal Cancer · Gastric Cancer · Esophageal Cancer
Primary: Unplanned Chemotherapy Treatment Delay — 16 Participants
Phase 3 N=298 Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma
Prostate Cancer
Primary: Number of Participants With Progression-Free Survival — 66; 84 Participants — p=0.40
Phase 2 N=97 Radiation Therapy and Chemotherapy Before and After Surgery in Treating Patients With Esophageal Cancer
Esophageal Cancer · Gastric Cancer
Primary: Pathologic Complete Response Rate — 15.4; 16.7 percentage of participants
Phase 3 N=564 S0500 Treatment Decision Making Based on Blood Levels of Tumor Cells for Metastatic Breast Cancer Treated With Chemo
Breast Cancer
Primary: Overall Survival — 10.7; 12.5 months — p=0.98
Phase 2 N=59 Chemoimmunotherapy Study for Patients With Epithelial Ovarian Cancer
Ovarian Cancer · Fallopian Tube Cancer · Peritoneal Cancer
Primary: Number of Patients With Response — 9; 21; 24 Participants
N/A N=45 Electrophysiological Biomarkers of Chemotherapy-related Cognitive Impairment and Recovery
Myelodysplastic Syndrome · Effects of Chemotherapy · Mild Cognitive Impairment
Primary: Change From Baseline Capture Task Performance at 1- and 3- Months — .103; -.039; .066; .067 change in proportional response time
N/A N=44 Programs To Support You During Chemotherapy
Depression · Fatigue · Stage IIA Colorectal Cancer
Primary: Fatigue Assessed by the Patient-Reported Outcomes Measurement Information System (PROMIS) — 53.1; 56.8; 53.0; 57.2 score on a scale
Phase 2 N=79 Combination Chemotherapy and Intensity-Modulated Radiation Therapy in Treating Patients Undergoing Surgery for Locally Advanced Rectal Cancer
Colorectal Cancer
Primary: The Percentage of Patients Experiencing Treatment-related Gastrointestinal Adverse Events ≥ Grade 2 Per National Cancer Institute (NCI) Common Terminology Criteria for…
N/A N=50 Impact of Adjuvant Chemotherapy on the Quality of Life of Patients Treated for Stage II / III Endometrial Cancer
Endometrial Cancer · Chemotherapy Effect · Quality of Life
Primary: The Impact in Terms of Overall Quality of Life of Adjuvant Chemotherapy by the QLQ-C30 Questionnaire — 61.7; 71.1 units on a scale
Phase 3 N=1,186 Comparison of Treatment Effect of Chemotherapy With Panitumumab to Chemotherapy Alone
Metastatic Colorectal Cancer
Primary: Progression-free Survival (PFS) — 5.9; 3.9; 5.0; 4.9 months — p=0.0036
Phase 2 N=31 Chemotherapy Followed by Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Locally Advanced Head And Neck Cancer
Head and Neck Cancer
Primary: Overall Response — 28 Participants
Phase 2 N=33 The Effect of a Mediterranean Diet Intervention on Cancer-related Fatigue and Mitochondrial Function During Chemotherapy
Cancer
Primary: The Number of Patients Who Enrolled Completed the Study. — 23; 10 Participants
Phase 3 N=345 Effects of GnRHa on Ovarian Function Against Chemotherapy-induced-gonadotoxicity
Breast Cancer
Primary: Number of Participants With Premature Ovarian Insufficiency — 10; 38 Participants
Phase 2 N=54 Chemotherapy AND Bcl-xL Inhibitor (AT-101) For Organ Preservation In Adults With Advanced Laryngeal Cancer
Laryngeal Cancer
Primary: Number of Patients Alive and Free From Indication for Laryngectomy Three Months Post Treatment — 27; 12 Participants
Phase 3 N=598 Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer
Non Small Cell Lung Cancer
Primary: Overall Survival — 26.81; 24.97 months — p=0.831